Elite Pharmaceuticals, Inc. in brief
Elite Pharmaceuticals, Inc. is a listed company in the Pharmaceutical industry, based in Northvale, New Jersey, USA. Its last known market value was $42 M (January 2022); there is no current figure. In the year to March 2026 it had sales of $149 M and a net profit of $45 M, about 30 cents of profit for every dollar of sales. It employs about 65 people. Its largest product and service lines by sales in 2026 were Manufacturing (99%), Manufacturing Fees (99%) and Scheduled Products Manufacturing Fees (95%).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc., a Nevada corporation was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly-owned subsidiary, Elite Laboratories, Inc., was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada.
We are a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products, and the manufacture of generic pharmaceuticals. Our strategy includes developing generic versions of controlled-release drug products with high barriers to entry.
From the company's annual report filed with the US SEC: read the report
Elite Pharmaceuticals, Inc. timeline
- 1998
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2012
- ✎Renamed Elite Pharmaceuticals Inc /Nv/Formerly Elite Pharmaceuticals Inc /De/.
- 2025
- 💰Record revenue of $149 millionFY2025, the highest of the 8 years on record.
- 💰Record net income of $45 millionFY2025, the highest profit of the 5 years on record.
Events of Elite Pharmaceuticals, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
Not enough history yet.
Key ratios
- P/E ratio (TTM)
- —
- Price / sales (TTM)
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin (TTM)
- 41.6%
- Operating margin
- 33.0%
- Return on equity
- 61.0%
- Liabilities / assets
- 28.5%
- Net debt
- $-7M
- Revenue growth
- +77.1%
- R&D / revenue
- 3.9%
- Revenue per employee
- $2.3 M
- Profit per employee
- $690 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Mar 2026 | $149M | +77.1% | $49M | $45M | 30.1% |
| Mar 2025 | $84M | +48.4% | $20M | $-4M | -5.1% |
| Mar 2024 | $57M | +65.8% | $11M | $20M | 35.5% |
| Mar 2023 | $34M | +5.9% | $4M | $4M | 10.4% |
| Mar 2022 | $32M | +27.1% | $5M | $9M | 27.6% |
| Mar 2021 | $25M | +41.1% | $2M | $5M | 20.1% |
| Mar 2020 | $18M | +137.6% | $-2M | $-2M | -12.5% |
| Mar 2019 | $8M | — | $-9M | $-9M | -122.6% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Mar 2026 | $24M | $1M | $23M | $0.03 | — |
| Mar 2025 | $7M | $2M | $6M | $0.00 | — |
| Mar 2024 | $-3M | $1M | $-4M | $0.02 | — |
| Mar 2023 | $3M | $6M | $-2M | $0.00 | — |
| Mar 2022 | $7M | $1M | $6M | $0.01 | — |
| Mar 2021 | $3M | — | — | $0.00 | — |
| Mar 2020 | $-2M | — | — | $0.00 | — |
| Mar 2019 | $-7M | — | — | $-0.01 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $40M (+10.4% on a year earlier), net income $17M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportRegulation FD disclosure
- Nov 3, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Aug 13, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-K/ACurrent report (amended)Regulation FD disclosure
- Aug 10, 20268-KCurrent reportRegulation FD disclosure
- Aug 4, 20268-KCurrent reportRegulation FD disclosure
- Jun 29, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jun 29, 202610-KAnnual report · period to Mar 2026
- Jun 23, 20268-KCurrent reportRegulation FD disclosure
Official filings of Elite Pharmaceuticals, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $149 M
- Operating income
- $49 M
- Net income
- $45 M
For year ending March-2026 · source: SEC filing
Balance sheet
- Total assets
- $138 M
- Total liabilities
- $39 M
- Total equity
- $99 M
As of March-2026
Insider trading at Elite Pharmaceuticals, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Barry H. DashDirector | Buy | +100,000 | $0.260 | $26 K | 3.37 M | Form 4 |
| filed | Barry H. DashDirector | Buy | +30,000 | $0.290 | $9 K | 3.27 M | Form 4 |
| filed | Douglas PlasscheEVP Operations | Option exercise | +2.50 M | $0.030 | $75 K | 6.00 M | Form 4 |
| filed | Douglas PlasscheEVP Operations | Sell | -800,000 | $0.620 | $496 K | 3.50 M | Form 4 |
| filed | Elite Pharmaceuticals Inc /NV/EVP Operations | Option exercise | +2.50 M | $0.030 | $75 K | 4.30 M | Form 4 |
| filed | Elite Pharmaceuticals Inc /NV/EVP Operations | Sell | -500,000 | $0.520 | $260 K | 1.80 M | Form 4 |
| filed | Kirko KirkovChief Commercial Officer | Buy | +16,366 | $0.590 | $10 K | 16,366 | Form 4 |
| filed | Douglas PlasscheEVP Operations | Sell | -200,000 | $0.580 | $116 K | 2.30 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Elite Pharmaceuticals, Inc. scorecard#
Passes 12 of the 15 checks that could be worked out: strongest in growth (6 of 6), weakest in financial health (2 of 3). Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth6 of 6
- ✓Revenue grew in the newest year77.1%Revenue up 77.1% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years63.3%63.3% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median63.3%63.3% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✓Earnings per share grew in the newest year0.03 vs 0.00Diluted EPS 0.03 in fiscal 2025 against 0.00 the year before (report's currency).
- ✓Net income higher than five years earlier$45 M$45 M in fiscal 2025 against $5 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability4 of 5
- ✓Profitable in the newest year$45 MNet income $45 M in fiscal 2025.
- ✗Profitable in each of the last five years4 of 5Profitable in 4 of the five years to fiscal 2025.
- ✓Operating margin above its peers' median33.0%33.0% against Pharmaceutical's median of 1.8% (74 companies).
- ✓Return on equity above 15%58.9%58.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier33.0%33.0% in fiscal 2025 against 10.8% in 2022.
Financial health2 of 3
- ✓Short-term assets cover short-term liabilities6.5×Current ratio 6.45 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✓Operating income covers interest five times446.4×Operating income 446.4 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year6.6%Diluted shares up 6.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Elite Pharmaceuticals, Inc.'s statements, beside the median of Pharmaceutical.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | 33.0% | 1.8% | |
| Net margin | 30.1% | -1.5% | |
| Return on equity | 58.9% | -0.9% | |
| Revenue growth, 3 years a year | 63.3% | 2.5% | |
| Revenue growth | 77.1% | 7.3% | |
| Free cash flow margin | 15.3% | 6.0% |
6of 8on the Piotroski tests of financial strength
- The share count rose 6.6% in the year.
- Receivables grew 104% while revenue grew 77%: customers are paying later, or sales were booked ahead of cash.
- Revenue has grown 8 years in a row.
Elite Pharmaceuticals, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Mar 31, 2026 | FY 2024to Mar 31, 2025 | FY 2023to Mar 31, 2024 | FY 2022to Mar 31, 2023 | FY 2021to Mar 31, 2022 | FY 2020to Mar 31, 2021 | FY 2019to Mar 31, 2020 | FY 2018to Mar 31, 2019 | FY 2017to Mar 31, 2018 | FY 2016to Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 149+77.1%100% | 84+48.4%100% | 57+65.8%100% | 34+5.9%100% | 32+27.1%100% | 25+41.0%100% | 18+138%100% | 7.6+1.5%100% | 7.5−22.6%100% | 9.6—100% | |
| Cost of revenue | 74+68.0%49.6% | 44+45.2%52.3% | 30+72.4%53.5% | 18+0.5%51.4% | 17+29.3%54.1% | 14+34.9%53.2% | 10+113%55.7% | 4.7+33.9%62.1% | 3.5−40.5%47.1% | 5.9—61.2% | |
| Gross profit | 75+87.2%50.4% | 40+52.1%47.7% | 26+58.8%46.5% | 17+12.2%48.6% | 15+24.7%45.9% | 12+48.7%46.8% | 8.0+178%44.3% | 2.9−27.4%37.9% | 3.9+5.6%52.9% | 3.7—38.8% | |
| Research and development | 5.7−27.9%3.9% | 8.0+15.7%9.5% | 6.9+11.0%12.2% | 6.2+53.0%18.2% | 4.1−20.8%12.6% | 5.1−7.6%20.1% | 5.5−27.2%30.7% | 7.6−21.0%100% | 9.6+15.9%129% | 8.3—86.1% | |
| General and administrative | 18+95.5%11.8% | 9.0+26.0%10.7% | 7.1+39.5%12.6% | 5.1+14.7%15.0% | 4.5+34.3%13.8% | 3.3−0.8%13.1% | 3.3+8.6%18.6% | 3.1+32.2%40.7% | 2.3+12.0%31.3% | 2.1—21.6% | |
| Operating expenses | 26+26.5%17.4% | 20+31.6%24.4% | 16+20.5%27.5% | 13+32.8%37.8% | 9.7−0.4%30.1% | 9.8−4.9%38.5% | 10−14.7%57.0% | 12−7.5%159% | 13+17.2%174% | 11—115% | |
| Operating income | 49+151%33.0% | 20+81.7%23.3% | 11+193%19.1% | 3.7−27.5%10.8% | 5.1+141%15.7% | 2.1—8.3% | −2.3—−12.7% | −9.2—−121% | −9.1—−121% | −7.4—−76.3% | |
| Interest and finance income | 0.2+892%0.1% | 0.0+0.1%0.0% | 0.0+181%0.0% | 0.0+5815%0.0% | 0.0−75.5%0.0% | 0.0−95.7%0.0% | 0.0−44.2%0.1% | 0.0+22.6%0.3% | 0.0+38.7%0.2% | 0.0—0.1% | |
| Interest expense and finance costs | 0.1−13.2%0.1% | 0.1−78.2%0.2% | 0.6−47.1%1.0% | 1.1+480%3.3% | 0.2−26.1%0.6% | 0.3−27.1%1.0% | 0.4−3.6%2.0% | 0.4+10.0%4.9% | 0.3+40.8%4.5% | 0.2—2.5% | |
| Other non-operating income (expense) | 7.7—5.2% | −20—−23.4% | −10−3432%−18.2% | 0.3−74.9%0.9% | 1.2−39.5%3.8% | 2.0+4235%8.0% | 0.0—0.3% | −0.8−118%−10.5% | 4.3−53.4%58.1% | 9.3—96.5% | |
| Income before tax | 57—38.2% | −0.1−111%−0.1% | 0.5−88.4%0.8% | 4.0−36.8%11.7% | 6.3+52.1%19.5% | 4.1—16.3% | −2.2—−12.4% | −10.0—−132% | −4.7−343%−63.3% | 1.9—20.2% | |
| Income tax | 12+180%8.0% | 4.3—5.1% | −20−4733%−34.7% | 0.4—1.2% | −1.7—−5.4% | — | — | −0.7—−8.9% | −1.0—−14.0% | −1.9—−19.4% | |
| Income from discontinued operations | — | — | — | — | — | — | 1.1—6.2% | — | — | — | |
| Net income including minority interests | — | — | — | — | — | — | −2.2—−12.5% | −9.3—−123% | — | — | |
| Net income attributable to shareholders | 45—30.1% | −4.3−121%−5.1% | 20+465%35.5% | 3.6−60.0%10.4% | 8.9+74.9%27.6% | 5.1—20.0% | −2.2—−12.5% | −9.3—−123% | −3.7−196%−49.2% | 3.8—39.5% | |
| Earnings per share, basic | 0.04—— | 0.00−100%— | 0.02—— | 0.00−100%— | 0.010.0%— | 0.01—— | 0.00—— | -0.01—— | 0.00−100%— | 0.03—— | |
| Earnings per share, diluted | 0.03—— | 0.00−100%— | 0.02—— | 0.00−100%— | 0.01—— | 0.00r0.01—— | 0.00—— | -0.01—— | -0.01—— | -0.01—— | |
| Shares, weighted average (basic) | 1,073+0.4%— | 1,068+5.2%— | 1,015+0.2%— | 1,013+0.2%— | 1,011+7.2%— | 943+13.3%— | 832+2.2%— | 814+2.3%— | 796−5.1%— | 839—— | |
| Shares, weighted average (diluted) | 1,138+6.6%— | 1,068+4.4%— | 1,023+1.0%— | 1,013+0.2%— | 1,011+7.2%— | 943−5.1%— | 993+21.7%— | 816+2.3%— | 798−5.5%— | 845—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 30+163%21.5% | 11+59.2%11.7% | 7.1−9.3%8.5% | 7.8−8.2%19.2% | 8.5+167%24.3% | 3.2+182%12.2% | 1.1−50.3%4.5% | 2.3−68.3%9.3% | 7.2−32.2%23.2% | 11—30.9% | |
| Receivables | 60+104%43.2% | 29+50.1%30.3% | 19+529%23.3% | 3.1+1.2%7.6% | 3.1−12.5%8.7% | 3.5−14.9%13.4% | 4.1+211%16.5% | 1.3+95.6%5.4% | 0.7−27.6%2.2% | 0.9—2.7% | |
| Inventory | 21+30.9%15.4% | 16+25.6%16.8% | 13+35.4%15.5% | 9.6+41.7%23.4% | 6.7+34.5%19.2% | 5.0+21.0%19.1% | 4.1−8.3%16.6% | 4.5−7.8%18.5% | 4.9−23.7%15.9% | 6.4—18.7% | |
| Other current assets | 1.3+36.5%1.0% | 1.0+86.3%1.0% | 0.5−49.2%0.6% | 1.0+96.0%2.5% | 0.5+7.0%1.5% | 0.5−43.4%1.9% | 0.9+17.4%3.5% | 0.7−21.9%3.0% | 0.9+103%3.1% | 0.5—1.4% | |
| Current assets | 112+94.2%81.1% | 58+44.3%59.9% | 40+86.0%47.8% | 22+14.0%52.6% | 19+54.7%53.7% | 12+19.0%46.6% | 10+15.7%41.1% | 8.9−35.4%36.3% | 14−25.6%44.4% | 18—53.7% | |
| Property, plant and equipment | 10−1.4%7.4% | 10+1.5%10.7% | 10−2.4%12.2% | 10+75.1%25.5% | 6.0−10.5%16.9% | 6.6−8.0%25.4% | 7.2−14.4%29.0% | 8.4−6.1%34.6% | 9.0−0.5%29.1% | 9.0—26.3% | |
| Right-of-use (leased) assets | 1.5−23.5%1.1% | 2.0−15.1%2.1% | 2.4+17931%2.8% | 0.0−98.7%0.0% | 1.0+381%2.9% | 0.2−40.9%0.8% | 0.4—1.5% | — | — | — | |
| Other intangible assets | 4.8−15.0%3.5% | 5.6−11.1%5.8% | 6.30.0%7.6% | 6.3−4.4%15.5% | 6.60.0%18.9% | 6.60.0%25.3% | 6.60.0%26.6% | 6.6−14.0%27.2% | 7.7+20.2%25.0% | 6.4—18.7% | |
| Total assets | 138+43.5%100% | 96+15.2%100% | 84+105%100% | 41+16.4%100% | 35+34.2%100% | 26+4.9%100% | 25+2.3%100% | 24−21.0%100% | 31−10.0%100% | 34—100% | |
| Accounts payable | 6.1+105%4.4% | 3.0+9.0%3.1% | 2.7+10.9%3.2% | 2.4+71.0%6.0% | 1.4+53.9%4.1% | 0.9−41.1%3.5% | 1.6+14.7%6.3% | 1.4−17.1%5.6% | 1.7+57.9%5.4% | 1.0—3.1% | |
| Current liabilities | 17+46.9%12.6% | 12−9.3%12.3% | 13+66.6%15.6% | 7.8+17.0%19.2% | 6.7+15.2%19.0% | 5.8−32.7%22.2% | 8.6+25.1%34.6% | 6.9+35.0%28.3% | 5.1+52.9%16.6% | 3.3—9.7% | |
| Lease liabilities (non-current) | 1.0−34.6%0.7% | 1.6−20.7%1.6% | 2.0—2.3% | — | 0.8+2051%2.4% | 0.0−76.7%0.1% | 0.2—0.7% | — | — | — | |
| Non-current liabilities | 22−29.1%15.9% | 31+138%32.2% | 13+217%15.6% | 4.1+26.9%10.0% | 3.2−23.5%9.2% | 4.2−25.4%16.1% | 5.7−7.2%22.7% | 6.1−16.4%25.0% | 7.3+37.5%23.6% | 5.3—15.5% | |
| Total liabilities | 39−8.1%28.5% | 43+64.4%44.5% | 26+118%31.2% | 12+20.2%29.2% | 9.9−1.1%28.2% | 10−29.8%38.3% | 14+10.0%57.3% | 13+4.8%53.3% | 12+43.5%40.2% | 8.6—25.2% | |
| Retained earnings | −76—−54.8% | −121—−125% | −116—−139% | −136—−334% | −140—−398% | −149—−569% | −154—−617% | −152—−622% | −143—−462% | −139—−405% | |
| Shareholders' equity | 99+84.8%71.5% | 54−7.1%55.5% | 58+98.8%68.8% | 29+14.8%70.8% | 25+56.2%71.8% | 16+51.6%61.7% | 11—42.7% | −2.5−155%−10.3% | 4.6−82.2%14.8% | 26—74.8% | |
| Total equity | — | — | — | — | — | 16+51.6%61.7% | 11—42.7% | −2.5—−10.3% | — | — | |
| Total liabilities and equity | 138+43.5%100% | 96+15.2%100% | 84+105%100% | 41+16.4%100% | 35+34.2%100% | 26+4.9%100% | 25+2.3%100% | 24−21.0%100% | 31−10.0%100% | 34—100% | |
| Shares outstanding | 1,077+0.8%— | 1,068+0.0%— | 1,068+5.4%— | 1,014+0.3%— | 1,011r1,011+0.2%— | 1,009+20.1%— | 840r840+1.9%— | 825+2.8%— | 803−13.5%— | 928—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 1.1−12.6%0.7% | 1.2−7.1%1.5% | 1.3+3.4%2.3% | 1.3+5.7%3.7% | 1.2−8.0%3.7% | 1.3−0.5%5.2% | 1.3+5.0%7.3% | 1.3+26.1%16.6% | 1.0+39.4%13.4% | 0.7—7.4% | |
| Share-based compensation | 0.2−22.4%0.1% | 0.2+42.3%0.3% | 0.2+307%0.3% | 0.0+174%0.1% | 0.0+8.9%0.0% | 0.0−78.8%0.1% | 0.1−54.5%0.3% | 0.1−44.3%1.8% | 0.2−31.6%3.3% | 0.4—3.7% | |
| Cash from operating activities | 24+219%16.0% | 7.5—8.9% | −3.2r−3.3−197%−5.7% | 3.3−48.7%9.8% | 6.5+104%20.2% | 3.2—12.6% | −1.8—−10.0% | −6.8—−89.8% | −4.8—−64.5% | −7.9—−81.8% | |
| Capital expenditure | −0.9—−0.6% | −1.6—−1.9% | −0.8—−1.4% | −5.7—−16.8% | −0.5—−1.5% | — | — | — | — | — | |
| Intangible assets bought | — | −0.9—−1.1% | — | — | — | — | — | — | −0.1—−1.3% | −0.0—−0.1% | |
| Cash from investing activities | −0.9—−0.6% | −2.4—−2.9% | −0.8—−1.4% | −5.7—−16.8% | −0.5—−1.5% | −0.3—−1.0% | −0.0−111%−0.2% | 0.3—4.4% | −0.3r−0.3—−3.7% | −1.1—−11.5% | |
| Debt repaid | — | — | — | — | — | — | — | — | −0.1—−1.1% | −0.2—−2.3% | |
| Shares issued | — | — | — | — | — | 0.0−97.1%0.2% | 1.4−30.3%8.0% | 2.1r2.1+3.2%27.3% | 2.0−73.7%26.8% | 7.6—78.8% | |
| Cash from financing activities | −4.3—−2.9% | −0.8−125%−1.0% | 3.3r3.4+96.2%5.9% | 1.7—5.0% | −0.7—−2.1% | −0.9−226%−3.4% | 0.7−56.0%3.8% | 1.6−6.2%20.7% | 1.7−79.3%22.4% | 8.1—83.7% | |
| Change in cash | 19+337%12.4% | 4.2—5.0% | −0.7—−1.2% | −0.7−113%−2.0% | 5.3—16.6% | — | −1.1—−6.3% | −4.9—−64.7% | −3.4r−3.4—−45.8% | −0.9—−9.5% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q2 FY2026to Sep 30, 2026 | Q1 FY2026to Jun 30, 2026 | Q4 FY2025to Mar 31, 2026 | Q3 FY2025to Dec 31, 2025 | Q2 FY2025to Sep 30, 2025 | Q1 FY2025to Jun 30, 2025 | Q4 FY2024to Mar 31, 2025 | Q3 FY2024to Dec 31, 2024 | Q2 FY2024to Sep 30, 2024 | Q1 FY2024to Jun 30, 2024 | Q4 FY2023to Mar 31, 2024 | Q3 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 145+17.8%100% | 40+10.4%100% | 32−19.5%100% | 41*+27.4%100% | 32+120%100% | 36+92.4%100% | 40+114%100% | 32*+78.3%100% | 14−7.6%100% | 19—100% | 19—100% | 18*—100% | 16—100% | |
| Cost of revenue | 82+40.2%56.3% | 24+8.3%60.1% | 19+45.1%58.3% | 20*+35.9%49.0% | 19+126%59.0% | 22+108%61.3% | 13+25.7%32.3% | 15*+49.5%45.9% | 8.2−3.0%57.4% | 11—56.6% | 10—54.9% | 9.8*—54.8% | 8.5—54.7% | |
| Gross profit | 63−2.3%43.7% | 16+13.6%39.9% | 14−50.4%41.7% | 21*+20.1%51.0% | 13+112%41.0% | 14+71.7%38.7% | 27+221%67.7% | 17*+113%54.1% | 6.1−13.1%42.6% | 8.2—43.4% | 8.5—45.1% | 8.1*—45.2% | 7.0—45.3% | |
| Research and development | 6.6−4.4%4.6% | 1.9+35.5%4.7% | 2.0+21.3%6.3% | 1.6*−19.6%4.0% | 1.0−42.0%3.3% | 1.4−29.5%3.8% | 1.7−22.6%4.2% | 2.0*+18.8%6.4% | 1.8+27.8%12.5% | 2.0—10.4% | 2.2—11.5% | 1.7*—9.6% | 1.4—9.0% | |
| General and administrative | 17+43.5%12.1% | 3.8−6.1%9.4% | 3.5+4.3%11.0% | 7.7*+278%18.9% | 2.5−9.5%7.8% | 4.0+77.2%11.1% | 3.4+72.9%8.5% | 2.0*−9.1%6.4% | 2.7+59.2%19.0% | 2.3—12.0% | 2.0—10.5% | 2.2*—12.5% | 1.7—11.0% | |
| Operating expenses | 27+17.8%18.3% | 6.1+3.5%15.1% | 6.0+8.2%18.5% | 11*+72.4%26.0% | 3.9−21.5%12.5% | 5.9+24.3%16.1% | 5.5+19.9%13.7% | 6.1*+39.9%19.2% | 5.0+43.1%35.0% | 4.7—25.0% | 4.6—24.5% | 4.4*—24.5% | 3.5—22.6% | |
| Operating income | 37−13.1%25.3% | 9.9+20.8%24.8% | 7.5−65.3%23.3% | 10*−8.7%25.0% | 9.0+721%28.5% | 8.2+136%22.6% | 22+462%54.0% | 11*+199%34.9% | 1.1−68.9%7.6% | 3.5—18.5% | 3.9—20.6% | 3.7*—20.8% | 3.5—22.7% | |
| Interest and finance income | 0.6+2954%0.4% | 0.2+4353%0.5% | 0.2+3557%0.5% | 0.1*+2417%0.3% | 0.1+1542%0.3% | 0.0−16.6%0.0% | 0.0−15.7%0.0% | 0.0*−5.6%0.0% | 0.0−3.0%0.0% | 0.0—0.0% | 0.0—0.0% | 0.0*—0.0% | 0.0—0.0% | |
| Interest expense and finance costs | 0.1−7.6%0.1% | 0.0−4.8%0.1% | 0.0−5.6%0.1% | 0.0*−7.8%0.1% | 0.0−11.6%0.1% | 0.0−14.8%0.1% | 0.0−17.4%0.1% | 0.0*−86.6%0.1% | 0.0−74.4%0.2% | 0.0—0.2% | 0.0—0.2% | 0.2*—1.2% | 0.1—0.8% | |
| Other non-operating income (expense) | 32—22.4% | 9.8+31.3%24.5% | 0.2—0.6% | 11*+31.4%26.2% | 12—37.4% | 7.5—20.6% | −22—−55.4% | 8.1*—25.4% | −12—−81.8% | −13—−68.9% | −3.0—−16.0% | −1.7*—−9.7% | −3.6—−23.3% | |
| Income before tax | 69+191%47.8% | 20+25.8%49.3% | 7.7—23.8% | 21*+8.2%51.2% | 21—66.0% | 16—43.2% | −0.6−167%−1.4% | 19*+867%60.2% | −11—−74.2% | −9.5—−50.4% | 0.8—4.5% | 2.0*—11.1% | −0.1—−0.6% | |
| Income tax | 8.9−9.7%6.1% | 2.4+22.0%6.1% | 1.8−66.1%5.6% | 2.4*+5.2%5.9% | 2.2+837%7.1% | 2.0+31.0%5.5% | 5.3+2194%13.2% | 2.3*—7.1% | 0.2—1.7% | 1.5—8.0% | 0.2—1.2% | −1.3*—−7.4% | −0.8—−5.2% | |
| Net income attributable to shareholders | 60+333%41.6% | 17+26.4%43.2% | 5.9—18.3% | 18*+8.6%45.3% | 19—58.9% | 14—37.7% | −5.9−1056%−14.6% | 17*+411%53.1% | −11−1642%−75.8% | −11—−58.5% | 0.6—3.3% | 3.3*—18.5% | 0.7—4.5% | |
| Earnings per share, basic | — | 0.02+100%— | 0.01—— | — | 0.02—— | 0.01—— | -0.01—— | — | -0.01—— | -0.01—— | 0.00—— | — | 0.00—— | |
| Earnings per share, diluted | — | 0.010.0%— | 0.01—— | — | 0.01—— | 0.01—— | -0.01—— | — | -0.01—— | -0.01—— | 0.00—— | — | 0.00—— | |
| Shares, weighted average (basic) | 1,077+0.5%— | 1,077+0.5%— | 1,077+0.8%— | — | 1,074+0.5%— | 1,072+0.3%— | 1,068+0.0%— | — | 1,068+5.3%— | 1,068—— | 1,068—— | — | 1,015—— | |
| Shares, weighted average (diluted) | 1,124−1.6%— | 1,124−1.6%— | 1,129+5.6%— | — | 1,141+6.8%— | 1,142+6.9%— | 1,068−0.7%— | — | 1,068+4.3%— | 1,068—— | 1,076—— | — | 1,024—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 35—24.2% | 35+31.0%24.2% | 39+79.1%27.9% | 30+163%21.5% | 21+154%16.7% | 27+179%22.7% | 22+159%19.5% | 11+59.2%11.7% | 8.3+42.6%9.1% | 9.6—10.8% | 8.4—9.6% | 7.1—8.5% | 5.8—7.8% | |
| Receivables | 63—43.8% | 63+54.7%43.8% | 50+39.3%36.1% | 60+104%43.2% | 49+163%38.4% | 41+90.6%34.9% | 36+76.8%32.5% | 29+50.1%30.3% | 18+15.3%20.3% | 21—24.3% | 20—23.3% | 19—23.3% | 16—21.4% | |
| Inventory | 23—15.6% | 23+24.0%15.6% | 24+25.0%17.3% | 21+30.9%15.4% | 25+24.5%19.9% | 18+28.2%15.5% | 19+39.9%17.4% | 16+25.6%16.8% | 20+40.7%22.2% | 14—16.1% | 14—15.7% | 13—15.5% | 14—19.2% | |
| Other current assets | 0.1—0.1% | 0.1−1.2%0.1% | 0.9+65.3%0.6% | 1.3+36.5%1.0% | 2.1+80.5%1.6% | 0.1+7.0%0.1% | 0.5+25.8%0.5% | 1.0+86.3%1.0% | 1.1+13.8%1.3% | 0.1—0.1% | 0.4—0.5% | 0.5—0.6% | 1.0—1.3% | |
| Current assets | 121—83.7% | 121+40.7%83.7% | 114+47.0%82.0% | 112+94.2%81.1% | 97+101%76.6% | 86+89.4%73.2% | 78+80.4%69.9% | 58+44.3%59.9% | 48+29.3%52.9% | 45—51.4% | 43—49.1% | 40—47.8% | 37—49.7% | |
| Property, plant and equipment | 11—7.8% | 11+10.9%7.8% | 11+4.5%7.7% | 10−1.4%7.4% | 10+1.7%7.9% | 10−0.8%8.6% | 10−2.8%9.2% | 10+1.5%10.7% | 9.9−2.3%10.9% | 10—11.5% | 11—12.0% | 10—12.2% | 10—13.5% | |
| Right-of-use (leased) assets | 1.3—0.9% | 1.3−28.0%0.9% | 1.4−25.6%1.0% | 1.5−23.5%1.1% | 1.7−21.8%1.3% | 1.8−15.2%1.5% | 1.9−15.1%1.7% | 2.0−15.1%2.1% | 2.1+7947%2.3% | 2.1—2.4% | 2.2—2.5% | 2.4—2.8% | 0.0—0.0% | |
| Other intangible assets | 4.8—3.3% | 4.8−15.0%3.3% | 4.8−15.0%3.4% | 4.8−15.0%3.5% | 5.6−22.1%4.5% | 5.6−22.1%4.8% | 5.6−22.1%5.1% | 5.6−11.1%5.8% | 7.2+14.2%8.0% | 7.2—8.2% | 7.2—8.2% | 6.3—7.6% | 6.3—8.5% | |
| Total assets | 144—100% | 144+23.1%100% | 140+25.4%100% | 138+43.5%100% | 126+39.3%100% | 117+32.9%100% | 111+26.7%100% | 96+15.2%100% | 91+21.5%100% | 88—100% | 88—100% | 84—100% | 75—100% | |
| Accounts payable | 3.1—2.1% | 3.1−9.6%2.1% | 5.6+9.9%4.0% | 6.1+105%4.4% | 6.5+11.7%5.2% | 3.4+72.7%2.9% | 5.1+95.2%4.6% | 3.0+9.0%3.1% | 5.8+102%6.4% | 2.0—2.2% | 2.6—3.0% | 2.7—3.2% | 2.9—3.9% | |
| Current liabilities | 18—12.6% | 18+70.1%12.6% | 30+183%21.8% | 17+46.9%12.6% | 13−10.2%10.4% | 11−17.0%9.1% | 11−23.2%9.7% | 12−9.3%12.3% | 15−23.3%16.2% | 13—14.6% | 14—16.0% | 13—15.6% | 19—25.6% | |
| Lease liabilities (non-current) | 0.7—0.5% | 0.7−44.2%0.5% | 0.9−38.9%0.6% | 1.0−34.6%0.7% | 1.2−31.0%0.9% | 1.3−25.7%1.1% | 1.4−23.0%1.3% | 1.6−20.7%1.6% | 1.7—1.8% | 1.7—2.0% | 1.9—2.1% | 2.0—2.3% | — | |
| Non-current liabilities | 4.0—2.8% | 4.0−91.2%2.8% | 4.4−91.7%3.2% | 22−29.1%15.9% | 33−16.9%26.0% | 45+60.2%38.4% | 53+239%47.5% | 31+138%32.2% | 40+334%43.7% | 28—31.8% | 16—17.7% | 13—15.6% | 9.1—12.2% | |
| Total liabilities | 22—15.3% | 22−60.3%15.3% | 35−45.3%24.9% | 39−8.1%28.5% | 46−15.1%36.5% | 56+36.0%47.5% | 64+115%57.2% | 43+64.4%44.5% | 54+92.0%59.8% | 41—46.4% | 30—33.7% | 26—31.2% | 28—37.9% | |
| Retained earnings | −53—−36.5% | −53—−36.5% | −70—−50.1% | −76—−54.8% | −94—−74.6% | −113—−96.3% | −127—−114% | −121—−125% | −138—−152% | −127—−144% | −116—−132% | −116—−139% | −120—−160% | |
| Shareholders' equity | 122—84.7% | 122+98.4%84.7% | 105+120%75.1% | 99+84.8%71.5% | 80+120%63.5% | 62+30.3%52.5% | 48−18.1%42.8% | 54−7.1%55.5% | 36−21.5%40.2% | 47—53.6% | 58—66.3% | 58—68.8% | 46—62.1% | |
| Total liabilities and equity | 144—100% | 144+23.1%100% | 140+25.4%100% | 138+43.5%100% | 126+39.3%100% | 117+32.9%100% | 111+26.7%100% | 96+15.2%100% | 91+21.5%100% | 88—100% | 88—100% | 84—100% | 75—100% | |
| Shares outstanding | 1,077—— | 1,077+0.4%— | 1,077+0.8%— | 1,077+0.8%— | 1,074+0.6%— | 1,073+0.5%— | 1,068+0.0%— | 1,068+0.0%— | 1,068+5.0%— | 1,068—— | 1,068—— | 1,068—— | 1,018—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 1.2+0.2%0.8% | 0.4+38.9%1.0% | 0.3−8.1%0.8% | 0.3*−13.2%0.6% | 0.3−14.2%0.9% | 0.3+21.1%0.8% | 0.3−14.5%0.7% | 0.3*−11.6%0.9% | 0.3r0.4−8.9%2.2% | 0.2r0.4—1.2% | 0.3—1.7% | 0.3*—1.8% | 0.3—2.2% | |
| Share-based compensation | 0.1−45.4%0.1% | 0.0−59.3%0.1% | 0.0−45.6%0.1% | 0.0*−44.3%0.1% | 0.0−36.1%0.1% | 0.0−4.6%0.1% | 0.10.0%0.1% | 0.1*0.0%0.2% | 0.1+41.7%0.5% | 0.1—0.3% | 0.1—0.3% | 0.1*—0.3% | 0.0—0.3% | |
| Cash from operating activities | 11−52.2%7.5% | −3.1*−160%−7.7% | 10−31.8%31.1% | 9.1*+133%22.4% | −5.3*—−16.7% | 5.1*+250%14.1% | 15+370%36.7% | 3.9*+86.6%12.2% | −1.1*—−7.4% | 1.5*—7.7% | 3.1—16.7% | 2.1r2.1*—11.7% | −2.4r−2.4*—−15.4% | |
| Capital expenditure | −2.1—−1.5% | −0.7*—−1.8% | −0.8—−2.5% | −0.4*—−1.0% | −0.2*—−0.7% | −0.1*—−0.3% | −0.2—−0.5% | −0.8*—−2.4% | 0*—0.0% | −0.1*—−0.5% | −0.8—−4.1% | −0.4*—−2.2% | — | |
| Intangible assets bought | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | −0.9—−4.8% | — | — | |
| Cash from investing activities | −2.1—−1.5% | −0.7*—−1.8% | −0.8—−2.5% | −0.4*—−1.0% | −0.2*—−0.7% | −0.1*−689%−0.3% | −0.2—−0.5% | −0.8*—−2.4% | 0*—0.0% | 0.0*—0.1% | −1.7—−8.8% | −0.4*—−2.2% | — | |
| Cash from financing activities | −0.5—−0.3% | −0.3*—−0.7% | −0.1—−0.4% | −0.0*—−0.1% | −0.0*—−0.1% | −0.1*—−0.3% | −4.1—−10.3% | −0.1*—−0.4% | −0.2*—−1.3% | −0.3*—−1.7% | −0.2—−0.9% | −0.4r−0.4*—−2.2% | −0.0r−0.0*—−0.2% | |
| Change in cash | 8.3−51.6%5.7% | −4.1*−183%−10.2% | 9.1−12.3%28.3% | 8.7*+188%21.4% | −5.5*—−17.5% | 4.9*+323%13.4% | 10+698%25.9% | 3.0*+134%9.5% | −1.3*—−8.7% | 1.2*—6.1% | 1.3—6.9% | 1.3*—7.2% | −2.8*—−18.2% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Elite Pharmaceuticals, Inc. sells: revenue by product line, fiscal 2026#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2025. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Manufacturing$148 M99%+80%
- Manufacturing Fees$148 M99%+80%
- Scheduled Products Manufacturing Fees$141 M95%+89%
- Indirect Sales to Wholesalers$83 M55%+143%
- Direct Sales to Wholesalers$65 M44%+36%
- Unscheduled Products Manufacturing Fees$6 M4.3%-12%
- Licensing$1 M0.7%-49%
- Unscheduled Products Licensing Fees$1 M0.4%-67%
- Scheduled Products Licensing Fees$0 M0.3%+88%
Source: SEC annual report (XBRL data) · as of Mar 31, 2026
Events at Elite Pharmaceuticals, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 1 · Results announced 9
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2009 | $1 M | A long-registered or listed company | Under $2 million | 1 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Elite Pharmaceuticals, Inc.#
1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $155 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Manager Product Development (Pharmaceutical)Natural Sciences Managers | 1 | $155 K |
Where: Northvale, NJ 1
| Fiscal year | Certified | Positions | Median wage | Filed |
|---|---|---|---|---|
| FY2025 | 1 | 1 | $155 K | 1 |
| FY2023 | 1 | 1 | $120 K | 1 |
| FY2022 | 2 | 2 | $138 K | 2 |
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Elite Pharmaceuticals, Inc.
How Elite Pharmaceuticals, Inc. compares in Pharmaceutical
- Revenue$149 M · higher than 25% of 324
- Net margin41.6% · higher than 98% of 313
- Revenue growth77.1% · higher than 93% of 107
- 🇮🇹 Pharmanutra S.p.A.$148 M
- 🇰🇷 Yungjin Pharm. Co., Ltd.$172 M
- 🇨🇦 Cronos Group Inc$1.2 B
- 🇺🇸 Athenex$144 M
- 🇨🇦 iAnthus Capital Holdings, Inc.$144 M
- 🇮🇳 Shilpa Medicare Limited$1.9 B
Peer comparison · Pharmaceutical
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Elite Pharmaceuticals, Inc.🇺🇸 | $42 M | — | 41.6% | +77.1% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Amgen Inc.🇺🇸 | $249.2 B | 26.5× | 24.1% | +9.9% |
| AstraZeneca PLC🇬🇧 | $242.6 B | 23.7× | 17.4% | +8.6% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Eli Lilly and Company$1.20 T
- Johnson & Johnson$652.5 B
- AbbVie Inc.$514.0 B
- Roche Holding AG$370.3 B
- Merck & Co., Inc.$359.8 B
- Novartis AG$286.8 B
Sources and freshness
- Market cap:
- Jan 7, 2022 (last known)
- Annual results:
- For year ending March-2026
- Balance sheet:
- As of March-2026
- Employees:
- As of June 25, 2026
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Elite Pharmaceuticals, Inc.? Verify and update this profile — free
Show Elite Pharmaceuticals, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.